Evogene Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
EVGN
IL0011050551
Biotechnology & Medical Research
Sales 2024 * | 17M 63.19M 1.36B | Sales 2025 * | 31.5M 117M 2.52B | Capitalization | 36.17M 134M 2.89B |
---|---|---|---|---|---|
Net income 2024 * | -20M -74.34M -1.6B | Net income 2025 * | -17M -63.19M -1.36B | EV / Sales 2024 * | 2.13 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.15 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Evogene Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 31/12/01 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 31/03/22 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/12/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 16/11/21 |
Sarit Firon
CHM | Chairman | 58 | 10/08/16 |
Leon Recanati
BRD | Director/Board Member | 76 | 30/04/05 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |